RSS-Feed abonnieren
DOI: 10.1055/s-2002-32104
Cyclooxygenase-2, Polypen und kolorektales Karzinom
Colorectal cancer and inhibition of cyclooxygenase-2Publikationsverlauf
11.3.2002
14.5.2002
Publikationsdatum:
07. Juni 2002 (online)

Klinische Populationsstudien zeigten, dass die Langzeiteinnahme von nicht-steroidalen Antiphlogistika (NSAID) das relative Risiko eines kolorektalen Karzinoms vermindert. Diese Studien waren die Basis für die Identifizierung der Cyclooxygenase (COX) 2. Die Behandlung von Patienten mit familiärer adenomatöser Polyposis (FAP) mit COX-2 Inhibitoren führte in der Tat zu einer Verminderung der Polypenzahl im Kolon. Die Einnahme der relativ nebenwirkungsarmen COX-2-Inhibitoren könnte damit eine antitumorale Strategie gegen das kolorektale Karzinom sein - eine Erkrankung, die weltweit jährlich über 550 000 Todesfälle fordert. Im Folgenden wird die COX-Funktion und deren Bedeutung für Pathogenese und Prävention des kolorektalen Karzinoms dargestellt.
Literatur
- 1
Bhattacharya M, Peri K G, Almazan G, Ribeiro-da-Silva A, Shichi H, Durocher Y, Abramovitz M, Hou X, Varma D R, Chemtob S.
Nuclear
localization of prostaglandin E2 receptors.
Proc Natl
Acad Sci USA.
1998;
95
15 792
MissingFormLabel
- 2
Dormond O, Foletti A, Paroz C, Ruegg C.
NSAIDs inhibit alpha V
beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell
spreading, migration and angiogenesis.
Nature Med.
2001;
7
1041
MissingFormLabel
- 3
DuBois R N, Radhika A, Reddy B S, Entingh A J.
Increased
cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors.
Gastroenterology.
1996;
110
1259
MissingFormLabel
- 4
Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N.
Up-regulation of
cyclooxygenase 2 gene expression in human colorectal adenomas and
adenocarcinomas.
Gastroenterology.
1994;
107
1183
MissingFormLabel
- 5
Gupta R A, DuBois R N.
Colorectal
cancer prevention and treatment by inhibition of cyclooxygenase-2.
Nature
Cancer Reviews.
2001;
1
11
MissingFormLabel
- 6
Karnes W E, Shattuck-Brandt R, Burgart L J, DuBois R N, Tester D J, Cunningham J M, Kim C Y, McDonnell S K, Schaid D J, Thibodeau S N.
Reduced
COX-2 protein in colorectal cancer with defective mismatch repair.
Cancer
Res.
1998;
58
5473
MissingFormLabel
- 7
Kinzler K W, Vogelstein B.
Landscaping the cancer
terrain.
Science.
1998;
280
1036
MissingFormLabel
- 8
Mann M, Sheng H, Shao J, Williams C S, Pisacane P I, Sliwkowski M X, DuBois R N.
Targeting cyclooxygenase 2 and HER-2/neu
pathways inhibits colorectal carcinoma growth.
Gastroenterology.
2001;
120
1713
MissingFormLabel
- 9
Marnett L J, Kalgutkar A S.
Cyclooxygenase
2 inhibitors: discovery, selectivity and the future.
Trends
Pharmacol Sci.
1999;
20
465
MissingFormLabel
- 10
Newberry R D, Stenson W F, Lorenz R G.
Cyclooxygenase-2-dependent arachidonic acid metabolites
are essential modulators of the intestinal immune response to dietary
antigen.
Nature Med.
1999;
5
900
MissingFormLabel
- 11
Reuter B K, Asfaha S, Buret A, Sharkey K A, Wallace J L.
Exacerbation of inflammation-associated
colonic injury in rat through inhibition of cyclooxygenase-2.
J
Clin Invest.
1996;
98
2076
MissingFormLabel
- 12
Sano H, Kawahito Y, Wilder R L, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T.
Expression of cyclooxygenase-1 and -2 in
human colorectal cancer.
Cancer Res.
1995;
55
3785
MissingFormLabel
- 13
Sinicrope F A, Lemoine M, Xi L, Lynch P M, Cleary K R, Shen Y, Frazier M L.
Reduced expression of cyclooxygenase 2 proteins
in hereditary nonpolyposis colorectal cancers relative to sporadic
cancers.
Gastroenterology.
1999;
117
350
MissingFormLabel
- 14
Smith W L, DeWitt D L, Garavito R M.
Cyclooxygenases: structural, cellular, and
molecular biology.
Ann Rev Biochem.
2000;
69
145
MissingFormLabel
- 15
Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo M M.
Acceleration
of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta
716) knockout mice.
Nature Med.
2001;
7
1048
MissingFormLabel
- 16
Steinbach G, Lynch P M, Phillips R K, Wallace M H, Hawk E, Gordon G B, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su L K, Levin B.
The effect
of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous
polyposis.
N Engl J Med.
2000;
342
1946
MissingFormLabel
- 17
Thun M J, Namboodiri M M, Heath C W.
Aspirin use and reduced risk of
fatal colon cancer.
N Engl J Med.
1991;
325
1593
MissingFormLabel
- 18
Torrance C J, Jackson P E, Montgomery E, Kinzler K W, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani C M.
Combinatorial chemoprevention
of intestinal neoplasia.
Nature Med.
2000;
6
1024
MissingFormLabel
- 19
Williams C S, Luongo C, Radhika A, Zhang T, Lamps L W, Nanney L B, Beauchamp R D, DuBois R N.
Elevated
cyclooxygenase-2 levels in Min mouse adenomas.
Gastroenterology.
1996;
111
1134
MissingFormLabel
- 20
Giardiello F M, Yang V W, Hylind L M, Krush A J, Petersen G M, Trimbath J D, Piantadosi S, Garrett E, Geimann D E, Hubbard W, Offerhaus G J, Hamilton S R.
Primary chemoprevention of familial
adenomatous polyposis with sulindac.
N Engl J Med.
2002;
346(14)
1054-9
MissingFormLabel
- 21
Suleiman S, Rex D K, Sonnenberg A M.
Chemoprevention of colorectal cancer by
aspirin: a cost-effectiveness analysis.
Gastroenterology.
2002;
122(1)
78-84
MissingFormLabel
- 22
Pai R, Soreghan B, Szabo I L, Pavelka M, Baatar D, Tarnawski A S.
Prostaglandin
E2 transactivates EGF receptor: a novel mechanism fpr promoting
colon cancer growth and gastrointestinal hypertrophy.
Nat
Med.
2002;
8(3)
289-93
MissingFormLabel
Priv.-Doz. Dr. med. Michael Geißler
Medizinische Klinik II
Hugstetter Straße 55
79106 Freiburg
Telefon: 0761/2703260
Fax: 0761/2703260
eMail: mgeissl@sun11.ukl.uni-freiburg.de